Compare XGN & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XGN | CPIX |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 73.6M |
| IPO Year | 2014 | 2007 |
| Metric | XGN | CPIX |
|---|---|---|
| Price | $2.70 | $4.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.86 | N/A |
| AVG Volume (30 Days) | 177.8K | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.70 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $42,010,949.00 |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $13.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.75 |
| 52 Week Low | $2.59 | $1.85 |
| 52 Week High | $12.23 | $6.27 |
| Indicator | XGN | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 70.42 |
| Support Level | $2.59 | $3.52 |
| Resistance Level | $3.29 | $4.41 |
| Average True Range (ATR) | 0.17 | 0.35 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 12.05 | 35.95 |
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.